Chattem Q1
This article was originally published in The Rose Sheet
Executive Summary
Net sales of Medicated Dandruff Shampoos increased 20% to $11.8 mil. due to "strong distribution" of Selsun Salon, which launched last fall, Chattem reports April 5. Sales of Selsun Blue were down "primarily due to increased media support and in-store promotional activity among competitive brands," Chattem adds. Medicated Skin Care net sales dropped 4% to $16.6 mil., but were up 13% when excluding pHisoderm, which was divested in 2005. Gold Bond grew 13% behind "strong sales" of Medicated Body Lotion and Ultimate Healing Lotion. Net sales were $84 mil., up 17%, or 23% excluding pHisoderm. Net income rose 70% to $14.8 mil., including a pre-tax gain of $8.6 mil. "related to a recovery, net of legal expenses, in the Dexatrim litigation settlement," Chattem notes...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.